Published in Recent Results Cancer Res on January 01, 1981
Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin (1982) 4.90
Evaluation of cancer information on the Internet. Cancer (1999) 4.55
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Mol Cell Biol (1994) 3.27
Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J Biol Chem (2000) 2.88
Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proc Natl Acad Sci U S A (1984) 2.74
DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep (1976) 2.59
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry (1989) 2.26
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res (2000) 2.14
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Effects of a physician communication intervention on patient care outcomes. J Gen Intern Med (1996) 2.06
Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer (1978) 2.04
Mitomycin C: a review. Cancer Treat Rev (1976) 1.92
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer (1975) 1.84
Chemical synthesis and expression of a cassette adapted ubiquitin gene. J Biol Chem (1987) 1.84
Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature (1988) 1.68
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
The pulmonary toxicity of antineoplastic agents. Semin Oncol (1982) 1.65
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev (1979) 1.60
Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A (1989) 1.58
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol (1989) 1.56
Properties of cloned and expressed human RNase H1. J Biol Chem (1999) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Reactivity to alcohol-related cues: physiological and subjective responses in alcoholics and nonproblem drinkers. J Stud Alcohol (1985) 1.50
Socioeconomic status and cancer survival. J Clin Oncol (1991) 1.48
Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci (1989) 1.48
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J (1988) 1.42
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 1.42
Phase II evaluation of adriamycin in human neoplasia. Cancer (1973) 1.40
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res (1992) 1.39
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res (1980) 1.38
Comprehensive reform of the new drug regulatory process. Biotechnology (N Y) (1995) 1.38
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am (2006) 1.38
Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL-1 cells. Mol Pharmacol (1988) 1.35
Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. Proc Natl Acad Sci U S A (1989) 1.30
Cloning and expression of a yeast copper metallothionein gene. Gene (1984) 1.30
Yeast metallothionein function in metal ion detoxification. J Biol Chem (1986) 1.28
Cost effective Internet access and video conferencing for a community cancer network. Proc Annu Symp Comput Appl Med Care (1995) 1.28
Chemotherapy of malignant fibrous histiocytoma: a Southwest Oncology Group report. Cancer (1977) 1.27
Bleomycin, a review. J Med (1976) 1.26
Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. J Biol Chem (1987) 1.26
Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry (1997) 1.23
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther (1998) 1.20
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res (1982) 1.18
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer (1972) 1.18
Leukotriene D4 treatment of bovine aortic endothelial cells and murine smooth muscle cells in culture results in an increase in phospholipase A2 activity. J Biol Chem (1986) 1.17
Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol (1998) 1.17
Vitravene--another piece in the mosaic. Antisense Nucleic Acid Drug Dev (1998) 1.16
Ubiquitin-metallothionein fusion protein expression in yeast. A genetic approach for analysis of ubiquitin functions. J Biol Chem (1988) 1.15
Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J Biol Chem (1997) 1.15
Cloning of a phospholipase A2-activating protein. Proc Natl Acad Sci U S A (1991) 1.13
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res (1991) 1.13
Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities. Mol Pharmacol (1986) 1.11
Investigating the structure of human RNase H1 by site-directed mutagenesis. J Biol Chem (2001) 1.09
Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep (1980) 1.09
Purification and characterization of a phosphoinositide-specific phospholipase C from guinea pig uterus. Phosphorylation by protein kinase C in vivo. J Biol Chem (1987) 1.09
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res (1987) 1.09
Early influence of popliteal vein repair in the treatment of popliteal vessel injuries. Am J Surg (1971) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc Natl Acad Sci U S A (1999) 1.07
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol (1996) 1.07
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res (1985) 1.07
Gene synthesis, expression, and processing of human ubiquitin carboxyl extension proteins. J Biol Chem (1989) 1.07
The implementation of telemedicine within a community cancer network. J Am Med Inform Assoc (1997) 1.07
Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res (1979) 1.05
Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer (1983) 1.05
Ifosfamide. J Natl Cancer Inst (1988) 1.03
Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. Mol Pharmacol (1987) 1.02
Interactions of 5-lipoxygenase with membranes: studies on the association of soluble enzyme with membranes and alterations in enzyme activity. Biochemistry (1988) 1.02
Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol (1985) 1.02
Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. Life Sci (1986) 1.01
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des (1997) 1.01
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res (1989) 1.01
Cognitive changes after alcohol cue exposure. J Consult Clin Psychol (1987) 1.00
Effect of leukotrienes, bradykinin and calcium ionophore (A 23187) on bovine endothelial cells: release of prostacyclin. Prostaglandins (1986) 1.00
Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells. Proc Natl Acad Sci U S A (1986) 1.00
Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: mechanism of signal transduction for leukotriene-D4 receptors. Mol Pharmacol (1987) 0.99
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J Med Chem (1987) 0.99
Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs (1987) 0.99
Acquired hypertrichosis languiginosa. Report of two new cases and a review of the literature. Cancer (1975) 0.98
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. J Biol Chem (1988) 0.98
Peptidoleukotrienes: distinct receptors for leukotriene C4 and D4 in the guinea-pig lung. Biochem Biophys Res Commun (1983) 0.98
In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther (1995) 0.97
Bleomycin. Ann Intern Med (1979) 0.97
More on reliability of death certificates. N Engl J Med (1981) 0.96
Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res (1982) 0.96
Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. Cancer Res (1988) 0.96
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest (1992) 0.95
In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res (1986) 0.95